Abstract
Significant advances are needed to improve the diagnosis, prognosis, and management of persons with CKD. Discovery of new biomarkers and improvements in currently available biomarkers for CKD hold great promise to achieve these necessary advances. Interest in identification and evaluation of biomarkers for CKD has increased substantially over the past decade. In 2009, the National Institute of Diabetes and Digestive and Kidney Diseases established the CKD Biomarkers Consortium (http://www.ckdbiomarkersconsortium.org/), a multidisciplinary, collaborative study group located at over a dozen academic medical centers. The main objective of the consortium was to evaluate new biomarkers for purposes related to CKD in established prospective cohorts, including those enriched for CKD. During the first 5 years of the consortium, many insights into collaborative biomarker research were gained that may be useful to other investigators involved in biomarkers research. These lessons learned are outlined in this Special Feature and include a wide range of issues related to biospecimen collection, storage, and retrieval, and the internal and external quality assessment of laboratories that performed the assays. The authors propose that investigations involving biomarker discovery and validation are greatly enhanced by establishing and following explicit quality control metrics, including the use of blind replicate and proficiency samples, by carefully considering the conditions under which specimens are collected, handled, and stored, and by conducting pilot and feasibility studies when there are concerns about the condition of the specimens or the accuracy or reproducibility of the assays.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 894-902 |
| Number of pages | 9 |
| Journal | Clinical Journal of the American Society of Nephrology |
| Volume | 10 |
| Issue number | 5 |
| DOIs | |
| State | Published - Jan 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
- Transplantation
- Epidemiology
- Critical Care and Intensive Care Medicine
Cite this
Cross-disciplinary biomarkers research : Lessons learned by the CKD biomarkers consortium. / CKD Biomarkers Consortium.
In: Clinical Journal of the American Society of Nephrology, Vol. 10, No. 5, 01.01.2015, p. 894-902.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cross-disciplinary biomarkers research
T2 - Lessons learned by the CKD biomarkers consortium
AU - CKD Biomarkers Consortium
AU - Hsu, Chi Yuan
AU - Ballard, Shawn
AU - Batlle, Daniel
AU - Bonventre, Joseph V.
AU - Böttinger, Erwin P.
AU - Feldman, Harold I.
AU - Klein, Jon B.
AU - Coresh, Josef
AU - Eckfeldt, John H.
AU - Inker, Lesley A.
AU - Kimmel, Paul L.
AU - Kusek, John W.
AU - Liu, Kathleen D.
AU - Mauer, Michael
AU - Mifflin, Theodore E.
AU - Molitch, Mark E.
AU - Nelsestuen, Gary L.
AU - Rebholz, Casey M.
AU - Rovin, Brad H.
AU - Sabbisetti, Venkata S.
AU - Van Eyk, Jennifer E.
AU - Vasan, Ramachandran S.
AU - Waikar, Sushrut S.
AU - Whitehead, Krista M.
AU - Nelson, Robert G.
AU - Ramachandran, Vasan S.
AU - Bonventre, Joseph
AU - Waikar, Sushrut
AU - Sabbisetti, Venkata
AU - Van Eyk, Jennifer
AU - Fu, Qin
AU - Brunner, Hermine
AU - D’Agati, Vivette
AU - Barasch, Jonathan
AU - Coresh, Josef
AU - Rebholz, Casey M.
AU - Go, Alan S.
AU - Böttinger, Erwin
AU - Teixeira, Avelino
AU - Daehn, Ilse
AU - Molitch, Mark
AU - Batlle, Daniel
AU - Rovin, Brad
AU - Wu, Haifeng
AU - Levey, Andrew S.
AU - Inker, Lesley A.
AU - Foster, Meredith C.
AU - Hsu, Chi Yuan
AU - Liu, Kathleen
AU - Molitoris, Bruce
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Significant advances are needed to improve the diagnosis, prognosis, and management of persons with CKD. Discovery of new biomarkers and improvements in currently available biomarkers for CKD hold great promise to achieve these necessary advances. Interest in identification and evaluation of biomarkers for CKD has increased substantially over the past decade. In 2009, the National Institute of Diabetes and Digestive and Kidney Diseases established the CKD Biomarkers Consortium (http://www.ckdbiomarkersconsortium.org/), a multidisciplinary, collaborative study group located at over a dozen academic medical centers. The main objective of the consortium was to evaluate new biomarkers for purposes related to CKD in established prospective cohorts, including those enriched for CKD. During the first 5 years of the consortium, many insights into collaborative biomarker research were gained that may be useful to other investigators involved in biomarkers research. These lessons learned are outlined in this Special Feature and include a wide range of issues related to biospecimen collection, storage, and retrieval, and the internal and external quality assessment of laboratories that performed the assays. The authors propose that investigations involving biomarker discovery and validation are greatly enhanced by establishing and following explicit quality control metrics, including the use of blind replicate and proficiency samples, by carefully considering the conditions under which specimens are collected, handled, and stored, and by conducting pilot and feasibility studies when there are concerns about the condition of the specimens or the accuracy or reproducibility of the assays.
AB - Significant advances are needed to improve the diagnosis, prognosis, and management of persons with CKD. Discovery of new biomarkers and improvements in currently available biomarkers for CKD hold great promise to achieve these necessary advances. Interest in identification and evaluation of biomarkers for CKD has increased substantially over the past decade. In 2009, the National Institute of Diabetes and Digestive and Kidney Diseases established the CKD Biomarkers Consortium (http://www.ckdbiomarkersconsortium.org/), a multidisciplinary, collaborative study group located at over a dozen academic medical centers. The main objective of the consortium was to evaluate new biomarkers for purposes related to CKD in established prospective cohorts, including those enriched for CKD. During the first 5 years of the consortium, many insights into collaborative biomarker research were gained that may be useful to other investigators involved in biomarkers research. These lessons learned are outlined in this Special Feature and include a wide range of issues related to biospecimen collection, storage, and retrieval, and the internal and external quality assessment of laboratories that performed the assays. The authors propose that investigations involving biomarker discovery and validation are greatly enhanced by establishing and following explicit quality control metrics, including the use of blind replicate and proficiency samples, by carefully considering the conditions under which specimens are collected, handled, and stored, and by conducting pilot and feasibility studies when there are concerns about the condition of the specimens or the accuracy or reproducibility of the assays.
UR - http://www.scopus.com/inward/record.url?scp=84929159515&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929159515&partnerID=8YFLogxK
U2 - 10.2215/CJN.11541114
DO - 10.2215/CJN.11541114
M3 - Article
VL - 10
SP - 894
EP - 902
JO - Clinical journal of the American Society of Nephrology : CJASN
JF - Clinical journal of the American Society of Nephrology : CJASN
SN - 1555-9041
IS - 5
ER -